Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 99

1.

The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset.

Ceol CJ, Houvras Y, Jane-Valbuena J, Bilodeau S, Orlando DA, Battisti V, Fritsch L, Lin WM, Hollmann TJ, Ferré F, Bourque C, Burke CJ, Turner L, Uong A, Johnson LA, Beroukhim R, Mermel CH, Loda M, Ait-Si-Ali S, Garraway LA, Young RA, Zon LI.

Nature. 2011 Mar 24;471(7339):513-7. doi: 10.1038/nature09806.

PMID:
21430779
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

The BRAF(V600E) causes widespread alterations in gene methylation in the genome of melanoma cells.

Hou P, Liu D, Dong J, Xing M.

Cell Cycle. 2012 Jan 15;11(2):286-95. doi: 10.4161/cc.11.2.18707. Epub 2012 Jan 15.

PMID:
22189819
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Ultraviolet radiation accelerates BRAF-driven melanomagenesis by targeting TP53.

Viros A, Sanchez-Laorden B, Pedersen M, Furney SJ, Rae J, Hogan K, Ejiama S, Girotti MR, Cook M, Dhomen N, Marais R.

Nature. 2014 Jul 24;511(7510):478-82. doi: 10.1038/nature13298. Epub 2014 Jun 11.

PMID:
24919155
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

BRAFV600E remodels the melanocyte transcriptome and induces BANCR to regulate melanoma cell migration.

Flockhart RJ, Webster DE, Qu K, Mascarenhas N, Kovalski J, Kretz M, Khavari PA.

Genome Res. 2012 Jun;22(6):1006-14. doi: 10.1101/gr.140061.112. Epub 2012 May 11. Erratum in: Genome Res. 2012 Jul;22(7):1382.

PMID:
22581800
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E mice.

Goel VK, Ibrahim N, Jiang G, Singhal M, Fee S, Flotte T, Westmoreland S, Haluska FS, Hinds PW, Haluska FG.

Oncogene. 2009 Jun 11;28(23):2289-98. doi: 10.1038/onc.2009.95. Epub 2009 Apr 27.

PMID:
19398955
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

DHODH modulates transcriptional elongation in the neural crest and melanoma.

White RM, Cech J, Ratanasirintrawoot S, Lin CY, Rahl PB, Burke CJ, Langdon E, Tomlinson ML, Mosher J, Kaufman C, Chen F, Long HK, Kramer M, Datta S, Neuberg D, Granter S, Young RA, Morrison S, Wheeler GN, Zon LI.

Nature. 2011 Mar 24;471(7339):518-22. doi: 10.1038/nature09882.

PMID:
21430780
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma.

Patton EE, Widlund HR, Kutok JL, Kopani KR, Amatruda JF, Murphey RD, Berghmans S, Mayhall EA, Traver D, Fletcher CD, Aster JC, Granter SR, Look AT, Lee C, Fisher DE, Zon LI.

Curr Biol. 2005 Feb 8;15(3):249-54.

PMID:
15694309
[PubMed - indexed for MEDLINE]
8.

BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition.

Haq R, Yokoyama S, Hawryluk EB, Jönsson GB, Frederick DT, McHenry K, Porter D, Tran TN, Love KT, Langer R, Anderson DG, Garraway LA, Duncan LM, Morton DL, Hoon DS, Wargo JA, Song JS, Fisher DE.

Proc Natl Acad Sci U S A. 2013 Mar 12;110(11):4321-6. doi: 10.1073/pnas.1205575110. Epub 2013 Feb 27.

PMID:
23447565
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

The role of BRAF mutation and p53 inactivation during transformation of a subpopulation of primary human melanocytes.

Yu H, McDaid R, Lee J, Possik P, Li L, Kumar SM, Elder DE, Van Belle P, Gimotty P, Guerra M, Hammond R, Nathanson KL, Dalla Palma M, Herlyn M, Xu X.

Am J Pathol. 2009 Jun;174(6):2367-77. doi: 10.2353/ajpath.2009.081057. Epub 2009 Apr 23.

PMID:
19389934
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis.

Vredeveld LC, Possik PA, Smit MA, Meissl K, Michaloglou C, Horlings HM, Ajouaou A, Kortman PC, Dankort D, McMahon M, Mooi WJ, Peeper DS.

Genes Dev. 2012 May 15;26(10):1055-69. doi: 10.1101/gad.187252.112. Epub 2012 May 1.

PMID:
22549727
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

[Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].

Lázár V.

Magy Onkol. 2013 Jun;57(2):96-9. doi: MagyOnkol.2013.57.2.96. Epub 2013 May 20. Hungarian.

PMID:
23795354
[PubMed - indexed for MEDLINE]
Free Article
12.

The genetic heterogeneity and mutational burden of engineered melanomas in zebrafish models.

Yen J, White RM, Wedge DC, Van Loo P, de Ridder J, Capper A, Richardson J, Jones D, Raine K, Watson IR, Wu CJ, Cheng J, Martincorena I, Nik-Zainal S, Mudie L, Moreau Y, Marshall J, Ramakrishna M, Tarpey P, Shlien A, Whitmore I, Gamble S, Latimer C, Langdon E, Kaufman C, Dovey M, Taylor A, Menzies A, McLaren S, O'Meara S, Butler A, Teague J, Lister J, Chin L, Campbell P, Adams DJ, Zon LI, Patton EE, Stemple DL, Futreal PA.

Genome Biol. 2013;14(10):R113.

PMID:
24148783
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development.

Cheung M, Sharma A, Madhunapantula SV, Robertson GP.

Cancer Res. 2008 May 1;68(9):3429-39. doi: 10.1158/0008-5472.CAN-07-5867.

PMID:
18451171
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma.

Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, Ramaswamy S, Beroukhim R, Milner DA, Granter SR, Du J, Lee C, Wagner SN, Li C, Golub TR, Rimm DL, Meyerson ML, Fisher DE, Sellers WR.

Nature. 2005 Jul 7;436(7047):117-22.

PMID:
16001072
[PubMed - indexed for MEDLINE]
Free Article
15.

Immunohistochemistry for histone h3 lysine 9 methyltransferase and demethylase proteins in human melanomas.

Miura S, Maesawa C, Shibazaki M, Yasuhira S, Kasai S, Tsunoda K, Maeda F, Takahashi K, Akasaka T, Masuda T.

Am J Dermatopathol. 2014 Mar;36(3):211-6. doi: 10.1097/DAD.0b013e3182964e02.

PMID:
24658378
[PubMed - indexed for MEDLINE]
16.

BRAF somatic mutations in malignant melanoma and melanocytic naevi.

Thomas NE.

Melanoma Res. 2006 Apr;16(2):97-103. Review.

PMID:
16567964
[PubMed - indexed for MEDLINE]
17.

Loss of expression of protein kinase C beta is a common phenomenon in human malignant melanoma: a result of transformation or differentiation?

Gilhooly EM, Morse-Gaudio M, Bianchi L, Reinhart L, Rose DP, Connolly JM, Reed JA, Albino AP.

Melanoma Res. 2001 Aug;11(4):355-69.

PMID:
11479424
[PubMed - indexed for MEDLINE]
18.

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.

Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, Chodon T, Nelson SF, McArthur G, Sosman JA, Ribas A, Lo RS.

Nature. 2010 Dec 16;468(7326):973-7. doi: 10.1038/nature09626. Epub 2010 Nov 24.

PMID:
21107323
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy.

Botton T, Yeh I, Nelson T, Vemula SS, Sparatta A, Garrido MC, Allegra M, Rocchi S, Bahadoran P, McCalmont TH, LeBoit PE, Burton EA, Bollag G, Ballotti R, Bastian BC.

Pigment Cell Melanoma Res. 2013 Nov;26(6):845-51. doi: 10.1111/pcmr.12148. Epub 2013 Aug 19.

PMID:
23890088
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Mutant V600E BRAF increases hypoxia inducible factor-1alpha expression in melanoma.

Kumar SM, Yu H, Edwards R, Chen L, Kazianis S, Brafford P, Acs G, Herlyn M, Xu X.

Cancer Res. 2007 Apr 1;67(7):3177-84.

PMID:
17409425
[PubMed - indexed for MEDLINE]
Free Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk